Patients categorized as prior relapsers or prior non-responders must have had at least one documented course of peginterferon (PegIFN)-based therapy (with or without ribavirin [RBV] ) for ≥12 consecutive weeks. Of the prior non-responder patients, some were classified as 'unknown' if further details about their prior treatment response were unavailable. Patients considered IFN-intolerant must have experienced IFN-and/or RBV-related adverse events (AEs) during prior treatment that led to treatment discontinuation. Included in the 'other' category were patients who had received previous IFN-based therapy with no on-treatment HCV RNA data available or undetectable HCV RNA within 2 months after end of prior treatment, or who received previous IFN-based therapy for <12 weeks and did not discontinue previous therapy due to IFN-and/or RBV-related AEs, or patients who had received non-IFN-based therapy (IFN with or without RBV), regardless of prior treatment response.
Simeprevir+sofosbuvir were taken together at the same time each day with food. Dose adjustments of simeprevir or sofosbuvir were not allowed. All study treatments were discontinued for patients who stopped treatment with either simeprevir for a duration exceeding 4 days and for patients with viral breakthrough defined as a confirmed increase in HCV RNA >1•0 log 10 from nadir, or confirmed HCV RNA >100 IU/mL in patients who had previously achieved HCV RNA <25 IU/mL.
Outcomes and procedures
A further secondary endpoint of the study was sustained virologic response 24 weeks after end of treatment (EOT; SVR24).
Blood samples to determine HCV RNA levels were collected at screening, on Days 1, 3, and 7, Weeks 2, 3, 4, 8, and 12, and post-treatment follow-up Weeks 4, 12, and 24. Plasma HCV RNA levels were quantified using the Roche TaqMan HCV/High Pure System (HPS) version 2•0 assay with a lower limit of quantification of 25 IU/mL and limit of detection of 15 IU/mL (Roche, USA).
Viral sequencing of the HCV NS3/4A and NS5B regions was performed at baseline in all patients and post-baseline in patients not achieving SVR to identify emerging HCV NS3/4A and NS5B amino acid substitutions. Amino acid substitutions at NS3 positions 43, 80, 122, 155, 156, and 168, at NS5B positions 96, 142, 159, 282, 316, 320, 321, 390, and 415, and at NS5A positions 28, 30, 31, 32, and 93 were considered. In addition, HCV NS5A sequencing was performed at baseline in all patients. IL28B genotype was determined at screening.
AEs were monitored throughout the study to post-treatment follow-up Week 4 and coded by Medical Dictionary for Regulatory Activities (MedDRA) preferred terms, with severity determined according to the World Health Organization (WHO) toxicity grading scale. Based on the safety profiles of simeprevir+sofosbuvir, AEs of special and clinical interest were taken into account. Increased bilirubin was considered an event of special interest. Events of clinical interest included rash (any type), photosensitivity conditions, pruritus, and dyspnea. Clinical laboratory assessments including hematology and urinalysis, and safety assessments including physical examination and vital signs, were conducted at screening, Days 1 and 7, Weeks 2, 4, 8, and 12, and post-treatment Week 4.
Patient-reported outcome (PRO) assessments were completed.
The Fatigue Severity Scale (FSS) is a nine-item scale. All nine items are combined to obtain a total FSS score, with higher values indicating a higher influence of fatigue on all items. 1 The Center for Epidemiologic Studies Depression (CES-D) scale is a 20-item scale. The score (0-3) for each of the individual items is summed to produce a total score (0-60). 2 The EuroQoL 5-Dimensions (EQ-5D) questionnaire Visual Analog Scale (VAS) uses a continuous score ranging from 0-100. 3 The HCV Symptom and Impact Questionnaire version 4 (HCV-SIQv4) is a self-administered 33-item questionnaire: 29 questions on the severity and frequency of symptoms, three questions regarding the impact of these symptoms on work/school attendance, and one question regarding the impact of these symptoms on daily activities. Higher HCV-SIQv4 scores indicate worse symptom severity, more time missed from work/school, and more impairment in daily activities. Changes from baseline in HCVSIQv4 overall body system score (OBSS) and individual body system scores (ie, for constitutional, gastrointestinal, psychiatric, neurocognitive, and integumentary symptoms) were calculated.
Statistical analysis
Mean changes from baseline in the following subgroups were explored for all PRO assessments: sustained virologic response 12 weeks after planned EOT (SVR12), age, sex, body mass index, and prior HCV treatment history. For FSS and HCV-SIQv4, mean changes from baseline were also explored for patients with the AEs of anemia and rash, respectively.
Results

Patient disposition
Overall, at the time of the primary analysis, 99/103 (96%) patients had completed treatment with simeprevir+sofosbuvir and 4/103 (4%) patients had discontinued all study treatment. Of the patients who discontinued, 2 (2%) patients discontinued due to an AE (infected bite and rash), 1 (1%) patient died in a road traffic accident, and 1 (1%) patient was non-adherent.
Efficacy
Of the 11 patients not achieving SVR12, with sequencing data available, and with emerging NS3 mutations at time of failure, 5 patients had a baseline Q80K polymorphism and 6 patients did not. The patients with a Q80K polymorphism at baseline had emerging mutations at positions D168E and R155K alone (2 patients and 1 patient, respectively) or combined (1 patient), or R155K+N174G (1 patient).
The patients without a Q80K polymorphism at baseline had emerging mutations at positions D168A (1 patient), D168V (4 patients), and R155K and I170T combined (1 patient).
Safety
Reported Grade 3 AEs included non-cardiac chest pain, cellulitis, limb injury, death due to a road traffic accident, anemia, cheilitis, and rash. The only Grade 4 AE reported was an infected bite.
Patient-reported outcomes
Most patients (78% [76/98]) completed all scheduled PRO questionnaires for all study visits.
In addition to the OBSS, the HCV-SIQv4 questionnaire provided results by individual body system. Psychiatric symptoms, constitutional (or general) symptoms and neurocognitive symptoms had the highest scores at baseline (Supporting table 4). At the SVR12 timepoint (Week 12 of follow-up) the largest improvements from baseline were observed for psychiatric symptoms and constitutional (or general) symptoms. Derived historical control SVR12 rate 70%
Supporting
* Sustained virologic response rates in IFN-intolerant patients were set to 5%, as no data with approved DAA/PegIFN/RBV regimens were available for this subgroup at the time of study design. † For conservative reasons, the SVR12 rate of the 'other' population was set to the same rate as for treatment-naïve patients.
DAA=direct-acting anti-viral agent; HCV=hepatitis C virus; PegIFN=peginterferon; RBV=ribavirin; SMV=simeprevir; SOF=sofosbuvir; SVR12=sustained virologic response 12 weeks after end of treatment. Data are n (%).
QD=once daily. Data are mean change from baseline (standard error).
Supporting table 2. Selected treatment-emergent laboratory abnormalities (intent-to-treat
* HCV-SIQv4 OBSS: range 0 (no symptoms) to 100 (maximum severity for all 29 symptoms), mean reduction of ≥10 points is clinically important. † FSS: range 1 (no fatigue) to 7 (severe fatigue), mean reduction of 0•6 points is clinically important.
‡ CES-D: range 0 (no depressive symptoms) to 60 (severe depression on 20 symptoms), mean reduction of ≥6 points is clinically important.
§ EQ-5D VAS: range 0 (worst possible health) to 100 (perfect health), changes from baseline of at least ±8 points are clinically important.
CES-D=Center for Epidemiologic Studies Depression Scale; EQ-5D VAS=EuroQol 5-Dimensions questionnaire Visual Analog Scale; FSS=Fatigue Severity Scale; HCV-SIQv4 OBSS=Hepatitis C Symptom and Impact Questionnaire version 4 Overall Body System Score; QD=once daily; SVR12=sustained virologic response at 12 weeks after end of treatment.
Supporting figure 1. OPTIMIST-2 study design.
QD=once daily; SVR12=sustained virologic response 12 weeks after end of treatment; SVR24=sustained virologic response 24 weeks after end of treatment. CES-D=Center for Epidemiologic Studies Depression Scale; EQ-5D VAS=EuroQol 5-Dimensions questionnaire Visual Analog Scale; FSS=Fatigue Severity Scale; FU=follow-up; HCV-SIQv4 OBSS=Hepatitis C Symptom and Impact Questionnaire version 4 Overall Body System Score; SE=standard error; WK, week.
